The clinical development of immunotherapies is undoubtedly one of the hottest areas in cancer research today. It is now well appreciated that the tumor microenvironment and the host immune system play important roles in cancer biology. With that understanding, modern-day immunotherapeutic approaches have emerged that do not directly target cancer cells, but harness the adaptive and innate powers of the immune system to combat cancer. These innovative strategies have been practice-changing for the management of a number of malignancies and continue to transform the way clinicians think about treating cancer. While the integration of landmark trial data and new strategies is occurring on an ongoing basis, preclinical and clinical data continue to rapidly accumulate on immunotherapy basic science.
The rapid pace with which new and practice-changing information is emerging creates practice and/or educational gaps for busy clinicians who strive to maintain state-of-the-art care for their patients with cancer. Educational initiatives that allow experts to place noteworthy evidence of immunotherapeutic strategies in its proper clinical context will bridge these educational gaps and optimize clinical practices.
The European Congress on Immunotherapies in Cancer™ is a 2-day comprehensive and interactive program focused exclusively on immunotherapies and their practical application to the management of cancer. This intensive, interactive program will provide a comprehensive review of key data sets that are most relevant for the clinician who manages some of the most difficult-to-treat forms of cancer. The program will focus on scientific advances, recent clinical trial results that shape current and evolving uses of these approaches, proactive methods to monitor and mitigate treatment-related adverse events, current and emerging testing methods, and multidisciplinary team approaches to optimize the use of immunotherapeutic strategies to treat cancer.
This educational activity is intended for medical oncologists and other healthcare professionals (physicians, physicians-in-training, oncology nurses, pharmacists, physician assistants, etc.). Participants will primarily be those whose practice requires mastery and a critical understanding of the fundamental principles, pivotal published studies, and emerging information on immunotherapies and their evolving roles in the treatment of cancer.
At the conclusion of this activity, you should be better prepared to:
Antoni Ribas, MD, PhD
Professor of Medicine
Professor of Surgery
Professor of Molecular and Medical Pharmacology
David Geffen School of Medicine
Director, Tumor Immunology Program
Jonsson Comprehensive Cancer Center
University of California, Los Angeles
Los Angeles, California, USA
Caroline Robert, MD PhD
Head of the Dermatology Unit
Department of Medicine
Gustave Roussy and Paris-Sud University
Villejuif Grand - Paris, France
Dec 31, 2018
Medical Crossfire®: Defining New Roles for the Application of PARP Inhibition Strategies in Multiple Tumor Types
Dec 31, 2018
Dec 31, 2018